Generation HD-2

Purpose

The purpose of this study is to test two different doses of tominersen versus placebo to select a dose that could potentially benefit individuals with prodromal (subtle, nonspecific signs of Huntington’s disease (HD)) or early stage manifest HD (definite signs of a motor disorder consistent with HD).

Who can participate

Males and Females between the ages of 25-50 years old, HD gene expansion mutation carrier. CAP score of 400-500 (at present or at the time of their next birthday), where CAP is calculated as follows: Age x (CAG repeat length – 33.66)

Principal Investigator

• Nicki Niemann, MD